ARGX
argenx NV ADRNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$48.85B
P/E Ratio
40.03
EPS
$19.53
Beta
-0.09
52W High
$934.62
52W Low
$510.06
50-Day MA
$760.30
200-Day MA
$779.33
Dividend Yield
—
Profit Margin
30.50%
Forward P/E
29.41
PEG Ratio
1.25
About argenx NV ADR
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Fundamentals
| Revenue (TTM) | $4.24B |
| Gross Profit (TTM) | $2.42B |
| EBITDA | $1.06B |
| Operating Margin | 27.40% |
| Return on Equity | 20.20% |
| Return on Assets | 8.86% |
| Revenue/Share (TTM) | $2.77 |
| Book Value | $4.73 |
| Price-to-Book | 6.63 |
| Price-to-Sales (TTM) | 11.53 |
| EV/Revenue | 10.66 |
| EV/EBITDA | 33.78 |
| Quarterly Earnings Growth (YoY) | -31.90% |
| Quarterly Revenue Growth (YoY) | 73.00% |
| Shares Outstanding | $62.19M |
| Float | $61.98M |
| % Insiders | 0.01% |
| % Institutions | 49.07% |
Historical Volatility
HV 10-Day
25.94%
HV 20-Day
26.54%
HV 30-Day
28.49%
HV 60-Day
30.65%
HV Rank
46.0%
Volatility is currently contracting
Analyst Ratings
Consensus ($1036.80 target)
6
Strong Buy15
Buy3
HoldData last updated: 5/1/2026